PD-L1 檢測市場：策略洞察與預測（2026-2035 年）

預計 PD-L1 檢測市場將從 2026 年的 12.7 億美元成長到 2035 年的 24.5 億美元，複合年成長率為 7.5%。

PD-L1檢測市場正經歷顯著的變革，其驅動力是轉向基於生物標記的免疫療法和精準腫瘤學的模式轉移。這一市場演變的特點是，人們日益認知到PD-L1表達可作為生物標記物，預測多種固體癌對免疫查核點抑制劑的反應。檢驗的免疫組織化學、數位病理學和人工智慧的融合，使得生物標記的評估更加標準化和可重複。由於免疫療法的選擇直接取決於生物標記的準確性，醫療系統正擴大將PD-L1檢測整合到常規診斷流程中。隨著免疫療法進入包括輔助性治療和輔助性治療在內的早期治療階段，其臨床應用範圍已從轉移性疾病擴展到其他領域，病理檢查室的檢測數量也不斷增加。監管機構持續加強伴隨診斷在癌症藥物核准中的作用，從而在藥物研發和診斷商業化之間形成結構性依賴關係。隨著市場上對自動化染色平台、數位病理解決方案和多生物標記技術的大量投資，PD-L1 檢測正在成為日益異質化的癌症患者群體中精準腫瘤學的基礎要素。

市場促進因素

免疫療法適應症的不斷擴大是PD-L1檢測市場的主要驅動力。 PD-L1檢測與免疫查核點抑制劑在腫瘤領域的臨床應用日益廣泛且密切相關。製藥公司正在獲得更多腫瘤類型和更早期治療階段的批准，這使得越來越多的患者需要在治療開始前進行生物標記評估。這種擴張持續推動了對具有可靠分析重複性和符合監管要求的伴隨診斷檢測的需求，進而促進了PD-L1檢測的持續成長。伴隨診斷的合作開發模式進一步加速了市場成長。由於監管機構通常要求藥物檢驗時使用經過驗證的生物標記物，伴隨診斷已成為癌症藥物開發的關鍵要素。製藥公司正在臨床開發專案的早期階段引入診斷合作夥伴，以簡化監管申報流程並加速商業化。這種合作開發模式促進了製藥公司和診斷試劑生產商之間的長期夥伴關係，並實現了監管申報的同步進行。數位病理學的應用正在推動診斷標準化和檢查室效率的提升。在PD-L1免疫組化檢測中，結果的變異性仍然是一個重大挑戰，因為不同的評分演算法和觀察者的經驗會影響臨床判斷。標準化結果的重要性日益凸顯，以確保不同醫療機構病患合格的一致性。診斷公司正在將人工智慧（AI）驅動的影像分析整合到數位病理平台中，以提高評分的可重複性和檢查室效率。多重生物標記評估透過提供更廣泛的生物學見解，正在改變精準腫瘤學。癌症生物學日益反映出腫瘤基因體學和免疫微環境之間的複雜相互作用。由於單一生物標記評估只能提供部分治療反應訊息，因此，將PD-L1與腫瘤突變負荷和免疫基因基因表現特徵等互補生物標記整合的多重診斷方法正成為日益成長的趨勢。

市場限制因素

PD-L1檢測方法、抗體克隆、評分演算法以及伴隨診斷要求的差異，持續阻礙各檢查室間結果的統一。缺乏標準化方案也為確保結果解讀的一致性和臨床可靠性帶來了挑戰。在某些晚期癌症中，組織樣本的取得仍然有限，這減少了檢測機會，並增加了重複切片檢查的需求。有限的組織樣本會限制進行全面生物標記評估的能力。實施數位病理基礎設施、自動化染色系統和品質保證程序的高昂成本，持續限制資源匱乏的醫療機構採用這些技術。購置先進設備和專業技術所需的大量投資，對小規模檢查室而言是一個障礙。複雜且區域性強的法規，給尋求將新型檢測方案商業化的診斷試劑生產商帶來了合規負擔。為了跟上不斷變化的監管環境，持續調整是必要的，但這會增加營運成本，並延長新產品的上市時間。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球PD-L1檢測市場：概述、市場規模與預測

• 市場定義和範圍
• 生物標記和疾病概述
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測
• 疾病負擔與未滿足的臨床需求
• 流行病學和患者人群分析
  • 癌症發生率
  • 確診患者人數
  • PD-L1 檢測的患者族群
• 伴隨診斷的現狀
• 腫瘤生物標記檢測的現狀
• 測試數量分析
• 臨床環境中的實施趨勢

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新興技術
• 產品創新
• 臨床試驗分析
• 管道分析
• 數位病理學的整合
• 人工智慧在PD-L1評估的應用

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章 全球PD-L1檢測市場：展望分析

• 分析：按技術平台
• 分析：依生物標記類型
• 分析：依樣本類型
• 分析：透過調查方法
• 分析：透過臨床應用

第9章 全球PD-L1檢測市場：細分市場分析

• 依產品
  • 裝置
  • 檢測試劑盒和試劑
  • 軟體和影像分析解決方案
• 透過技術
  • 免疫組織化學（IHC）
  • 多重螢光
  • 其他技術
• 適應症
  • 肺癌
  • 黑色素瘤
  • 乳癌
  • 胃癌及胃食道交界處癌
  • 子宮頸癌
  • 其他癌症
• 依樣本類型
  • 組織切片檢查
  • 液態生物檢體
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 其他

第10章 全球PD-L1檢測市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球PD-L1檢測市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 韓國
• 印度
• 澳洲
• 巴西
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• Agilent Technologies
• Hologic, Inc.
• Abbott Laboratories
• Bio-Techne Corporation
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• QIAGEN NV
• PerkinElmer, Inc.

第14章 全球PD-L1檢測市場：商業預測分析

第15章：投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The PD-L1 Testing Market is expected to grow at a CAGR of 7.5% from a market value of USD 1.27 billion in 2026 to USD 2.45 billion in 2035.

The PD-L1 testing market is undergoing significant transformation driven by the paradigm shift toward biomarker-guided immunotherapy and precision oncology. The market's evolution is characterized by the growing recognition that PD-L1 expression serves as a predictive biomarker for immune checkpoint inhibitor response across multiple solid tumors. The convergence of validated immunohistochemistry assays, digital pathology, and artificial intelligence is enabling more standardized and reproducible biomarker assessment. Healthcare systems are increasingly integrating PD-L1 testing into routine diagnostic pathways because treatment selection for immunotherapies directly depends on biomarker accuracy. Clinical adoption is extending beyond metastatic disease because immunotherapy is moving into earlier treatment settings, including neoadjuvant and adjuvant therapy, increasing testing volumes in pathology laboratories. Regulatory agencies continue strengthening the role of companion diagnostics in oncology drug approvals, creating a structural dependency between pharmaceutical development and diagnostic commercialization. The market is witnessing significant investment in automated staining platforms, digital pathology solutions, and multiplex biomarker technologies, positioning PD-L1 testing as a foundational component of precision oncology across increasingly heterogeneous cancer populations.

Market Drivers

The expanding immunotherapy indications represent the primary driver for the PD-L1 testing market. PD-L1 testing remains closely linked to the expanding clinical use of immune checkpoint inhibitors across oncology. Pharmaceutical sponsors are obtaining approvals for additional tumor types and earlier treatment settings, increasing the number of patients requiring biomarker evaluation before therapy initiation. This expansion creates sustained demand for validated companion diagnostic assays that demonstrate analytical reproducibility and regulatory compliance, resulting in sustained growth in PD-L1 testing utilization. The companion diagnostic co-development model is further accelerating market growth. Companion diagnostics represent an essential component of oncology drug development because regulatory authorities frequently require validated biomarkers during therapeutic approval. Pharmaceutical developers are integrating diagnostic partners into clinical development programs earlier to streamline regulatory submissions and accelerate commercial launches. This co-development model encourages long-term partnerships between pharmaceutical companies and diagnostic manufacturers while enabling synchronized regulatory submissions. Digital pathology adoption is improving diagnostic standardization and laboratory efficiency. Interpretation variability remains a significant challenge for PD-L1 immunohistochemistry because different scoring algorithms and observer experience may influence clinical decisions. Healthcare systems increasingly recognize the importance of standardized interpretation to ensure consistent patient eligibility across institutions. Diagnostic companies are integrating artificial intelligence-assisted image analysis with digital pathology platforms to improve scoring reproducibility and laboratory efficiency. Multiplex biomarker assessment is reshaping precision oncology by enabling broader biological insight. Cancer biology increasingly reflects complex interactions between tumor genomics and the immune microenvironment. Single biomarker evaluation provides only partial insight into therapeutic response, encouraging broader adoption of multiplex diagnostic approaches that integrate PD-L1 with complementary biomarkers, including tumor mutational burden and immune gene expression signatures.

Market Restraints

Variability among PD-L1 assays, antibody clones, scoring algorithms, and companion diagnostic requirements continues to limit result harmonization across laboratories. The lack of standardized protocols creates challenges for consistent interpretation and clinical confidence. Tissue availability remains constrained in several advanced cancers, reducing testing opportunities and increasing the need for repeat biopsy procedures. Limited tissue samples can restrict the ability to perform comprehensive biomarker assessment. High implementation costs for digital pathology infrastructure, automated staining systems, and quality assurance programs continue restricting adoption in resource-limited healthcare settings. The significant investment required for advanced instrumentation and expertise creates barriers for smaller laboratories. Regulatory complexities across different jurisdictions create compliance burdens for diagnostic manufacturers seeking to commercialize new testing solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated pathology workflows. Immunohistochemistry remains the clinical standard for PD-L1 assessment because virtually all approved companion diagnostics rely on validated IHC assays linked to regulatory-approved immunotherapies. Demand is expanding as hospitals continue integrating biomarker-guided treatment pathways into routine oncology practice, increasing the need for standardized tissue-based testing. Digital pathology adoption is expanding because laboratories require scalable interpretation workflows that reduce interobserver variability. Multiplex immunofluorescence and spatial biology technologies are gaining clinical relevance as oncologists increasingly evaluate PD-L1 alongside genomic, immune, and transcriptomic biomarkers. The segment analysis reveals that assay kits and reagents represent the largest demand center because every patient evaluation requires standardized consumables regardless of laboratory size or testing frequency. Clinical adoption is increasing as immune checkpoint inhibitors receive approvals across additional tumor types, causing pathology laboratories to process higher testing volumes. Lung cancer represents the largest clinical application because immune checkpoint inhibitors constitute a major treatment option for both metastatic and earlier-stage non-small cell lung cancer. Melanoma maintains substantial dependence on PD-L1 assessment because immune checkpoint blockade remains a foundational therapeutic approach. Breast cancer, particularly triple-negative breast cancer, increasingly incorporates PD-L1 testing into treatment selection as immunotherapy indications continue expanding. Diagnostic laboratories account for a substantial proportion of PD-L1 testing because centralized pathology services provide standardized interpretation, quality assurance, and high-throughput testing capabilities. The integration of AI is becoming increasingly important because growing pathology workloads require scalable diagnostic workflows that improve efficiency without compromising analytical quality. AI is supporting automated tissue recognition, standardized PD-L1 scoring, quality control, and clinical reporting within digital pathology environments.

Competitive and Strategic Outlook

The competitive landscape features established pathology diagnostic companies alongside specialized companion diagnostic providers. F. Hoffmann-La Roche remains a global leader in companion diagnostics through its Ventana pathology portfolio and long-standing collaborations with immuno-oncology drug developers, continuing to strengthen automated tissue diagnostics and digital pathology capabilities. Agilent Technologies expands its PD-L1 testing portfolio through Dako companion diagnostic assays that support multiple approved immunotherapies, focusing on assay standardization, laboratory automation, and integrated pathology solutions. Abbott leverages its global diagnostics infrastructure to support precision oncology through molecular and immunodiagnostic technologies, continuing to invest in advanced diagnostic platforms. Thermo Fisher Scientific provides comprehensive pathology instruments, antibodies, reagents, and molecular diagnostic solutions supporting oncology research and clinical laboratories. QIAGEN strengthens precision oncology through molecular diagnostic assays, bioinformatics solutions, and companion diagnostic collaborations. Bio-Rad supports oncology diagnostics through high-quality antibodies, reagents, digital PCR systems, and laboratory quality control products. Bio-Techne focuses on advanced antibodies, multiplex immunoassays, spatial biology, and cell analysis technologies. Merck KGaA supports precision oncology through life science research reagents, antibodies, and laboratory technologies used in biomarker development. Companies are pursuing product portfolio expansion through innovation in automated staining platforms, digital pathology solutions, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside immunotherapies. Recent key developments include Agilent Technologies receiving FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform to identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma eligible for treatment with KEYTRUDA. Abbisko Therapeutics and AstraZeneca entered into a strategic collaboration to conduct a Phase I/II trial combining lumipodlin with Tagrisso for patients with EGFR-mutated and PD-L1-positive NSCLC. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The PD-L1 testing market is positioned for sustained growth driven by the convergence of immunotherapy expansion, companion diagnostic co-development, and digital pathology innovation. The transition from single-marker companion diagnostics toward integrated immune profiling represents a fundamental shift in precision oncology. While challenges related to assay variability, tissue availability, and implementation costs persist, strategic investments in technology, standardization, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with PD-L1 testing evolving into a foundational biomarker within broader precision oncology platforms that integrate genomic, transcriptomic, and immune profiling to support increasingly personalized cancer treatment strategies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global PD-L1 Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Biomarker and Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden & Unmet Clinical Needs
• 3.8 Epidemiology and Patient Population Analysis
  • 3.8.1 Cancer Incidence
  • 3.8.2 Diagnosed Patient Population
  • 3.8.3 Eligible Population for PD-L1 Testing
• 3.9 Companion Diagnostics Landscape
• 3.10 Biomarker Testing Landscape in Oncology
• 3.11 Testing Volume Analysis
• 3.12 Clinical Adoption Trends

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Digital Pathology Integration
• 6.6 Artificial Intelligence Integration in PD-L1 Assessment

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global PD-L1 Testing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Testing Methodology
• 8.5 Analysis by Clinical Application

9. Global PD-L1 Testing Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Assay Kits & Reagents
  • 9.1.3 Software & Image Analysis Solutions
• 9.2 By Technology
  • 9.2.1 Immunohistochemistry (IHC)
  • 9.2.2 Multiplex Immunofluorescence
  • 9.2.3 Other Technologies
• 9.3 By Indication
  • 9.3.1 Lung Cancer
  • 9.3.2 Melanoma
  • 9.3.3 Breast Cancer
  • 9.3.4 Gastric & Gastroesophageal Junction Cancer
  • 9.3.5 Cervical Cancer
  • 9.3.6 Other Cancer Types
• 9.4 By Sample Type
  • 9.4.1 Tissue Biopsy
  • 9.4.2 Liquid Biopsy
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Others

10. Global PD-L1 Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global PD-L1 Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Agilent Technologies
• 13.3 Hologic, Inc.
• 13.4 Abbott Laboratories
• 13.5 Bio-Techne Corporation
• 13.6 Thermo Fisher Scientific Inc.
• 13.7 Merck KGaA
• 13.8 Bio-Rad Laboratories, Inc.
• 13.9 QIAGEN N.V.
• 13.10 PerkinElmer, Inc.

14. Global PD-L1 Testing Market Commercial Forecast Analysis

• 14.1 PD-L1 IHC 22C3 pharmDx
• 14.2 PD-L1 IHC 28-8 pharmDx
• 14.3 VENTANA PD-L1 (SP142) Assay
• 14.4 VENTANA PD-L1 (SP263) Assay
• 14.5 Other Commercial PD-L1 Testing Assays

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends